Two CISOs dissect the Axios npm attack, revealing a self-erasing RAT, CI/CD compromise risks and why open-source software ...

The unified JavaScript runtime standard is an idea whose time has come. Here’s an inside look at the movement for server-side JavaScript interoperability. The WinterCG community group was recently ...

Nearly two years after Google DeepMind released AlphaFold 3, an updated version of its system for predicting protein structure that is geared towards drug discovery, its biopharmaceuticals spin-off, ...

The unveiling of the Isomorphic Labs Drug Design Engine (IsoDDE) represents a fundamental shift from merely predicting the shape of biological life to actively engineering its functions. While ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.

In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s secretive drug discovery arm, Isomorphic Labs, is getting ready to ...

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. The news comes as tech ...

Add Yahoo as a preferred source to see more of our stories on Google. In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min In addition to news coming out ...